Allyson M Morton1, Manja Koch1, Carlos O Mendivil1,2,3, Jeremy D Furtado1, Anne Tjønneland4, Kim Overvad5,6, Liyun Wang1, Majken K Jensen1,7, Frank M Sacks1,7,8. 1. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. 2. Department of Medicine, Universidad de los Andes, Bogotá, Colombia. 3. Section of Endocrinology, Department of Internal Medicine, Fundación Santa Fe de Bogotá, Bogotá, Colombia. 4. Danish Cancer Society Research Center, Copenhagen, Denmark. 5. Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark. 6. Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark. 7. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 8. Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Subspecies of HDL contain apolipoprotein E (apoE) and/or apoCIII. Both proteins have properties that could affect HDL metabolism. The relation between HDL metabolism and risk of coronary heart disease (CHD) is not well understood. METHODS:Eighteen participants were given a bolus infusion of [D3]L-leucine to label endogenous proteins on HDL. HDL was separated into subspecies containing apoE and/or apoCIII and then into 4 sizes. Metabolic rates for apoA-I in HDL subspecies and sizes were determined by interactive modeling. The concentrations of apoE in HDL that contain or lack apoCIII were measured in a prospective study in Denmark including 1,949 incident CHD cases during 9 years. RESULTS:HDL containing apoE but not apoCIII is disproportionately secreted into the circulation, actively expands while circulating, and is quickly cleared. These are key metabolic steps in reverse cholesterol transport, which may protect against atherosclerosis. ApoCIII on HDL strongly attenuates these metabolic actions of HDL apoE. In the epidemiological study, the relation between HDL apoE concentration and CHD significantly differed depending on whether apoCIII was present. HDL apoE was associated significantly with lower risk of CHD only in the HDL subspecies lacking apoCIII. CONCLUSIONS: ApoE and apoCIII on HDL interact to affect metabolism and CHD. ApoE promotes metabolic steps in reverse cholesterol transport and is associated with lower risk of CHD. ApoCIII, when coexisting with apoE on HDL, abolishes these benefits. Therefore, differences in metabolism of HDL subspecies pertaining to reverse cholesterol transport are reflected in differences in association with CHD. TRIAL REGISTRATION: Clinicaltrials.gov NCT01399632. FUNDING: This work was supported by NIH grant R01HL095964 to FMS and by a grant to the Harvard Clinical and Translational Science Center (8UL1TR0001750) from the National Center for Advancing Translational Science.
RCT Entities:
BACKGROUND: Subspecies of HDL contain apolipoprotein E (apoE) and/or apoCIII. Both proteins have properties that could affect HDL metabolism. The relation between HDL metabolism and risk of coronary heart disease (CHD) is not well understood. METHODS: Eighteen participants were given a bolus infusion of [D3]L-leucine to label endogenous proteins on HDL. HDL was separated into subspecies containing apoE and/or apoCIII and then into 4 sizes. Metabolic rates for apoA-I in HDL subspecies and sizes were determined by interactive modeling. The concentrations of apoE in HDL that contain or lack apoCIII were measured in a prospective study in Denmark including 1,949 incident CHD cases during 9 years. RESULTS: HDL containing apoE but not apoCIII is disproportionately secreted into the circulation, actively expands while circulating, and is quickly cleared. These are key metabolic steps in reverse cholesterol transport, which may protect against atherosclerosis. ApoCIII on HDL strongly attenuates these metabolic actions of HDL apoE. In the epidemiological study, the relation between HDL apoE concentration and CHD significantly differed depending on whether apoCIII was present. HDL apoE was associated significantly with lower risk of CHD only in the HDL subspecies lacking apoCIII. CONCLUSIONS:ApoE and apoCIII on HDL interact to affect metabolism and CHD. ApoE promotes metabolic steps in reverse cholesterol transport and is associated with lower risk of CHD. ApoCIII, when coexisting with apoE on HDL, abolishes these benefits. Therefore, differences in metabolism of HDL subspecies pertaining to reverse cholesterol transport are reflected in differences in association with CHD. TRIAL REGISTRATION: Clinicaltrials.gov NCT01399632. FUNDING: This work was supported by NIH grant R01HL095964 to FMS and by a grant to the Harvard Clinical and Translational Science Center (8UL1TR0001750) from the National Center for Advancing Translational Science.
Authors: Anne Tjønneland; Anja Olsen; Katja Boll; Connie Stripp; Jane Christensen; Gerda Engholm; Kim Overvad Journal: Scand J Public Health Date: 2007 Impact factor: 3.021
Authors: Carlos O Mendivil; Jeremy Furtado; Allyson M Morton; Liyun Wang; Frank M Sacks Journal: Arterioscler Thromb Vasc Biol Date: 2015-11-05 Impact factor: 8.311
Authors: Allison B Andraski; Sasha A Singh; Lang Ho Lee; Hideyuki Higashi; Nathaniel Smith; Bo Zhang; Masanori Aikawa; Frank M Sacks Journal: Arterioscler Thromb Vasc Biol Date: 2019-09-26 Impact factor: 8.311
Authors: Jeremy D Furtado; Rain Yamamoto; John T Melchior; Allison B Andraski; Maria Gamez-Guerrero; Patrick Mulcahy; Zeling He; Tianxi Cai; W Sean Davidson; Frank M Sacks Journal: Arterioscler Thromb Vasc Biol Date: 2018-12 Impact factor: 8.311
Authors: Frank M Sacks; Liang Liang; Jeremy D Furtado; Tianxi Cai; W Sean Davidson; Zeling He; Robyn L McClelland; Eric B Rimm; Majken K Jensen Journal: Arterioscler Thromb Vasc Biol Date: 2020-09-10 Impact factor: 8.311
Authors: Manja Koch; Sarah A Aroner; Annette L Fitzpatrick; W T Longstreth; Jeremy D Furtado; Kenneth J Mukamal; Majken K Jensen Journal: Stroke Date: 2021-10-14 Impact factor: 7.914
Authors: Rain Yamamoto; Majken K Jensen; Sarah Aroner; Jeremy D Furtado; Bernard Rosner; Frank B Hu; Beverley Balkau; Andrea Natali; Ele Ferrannini; Simona Baldi; Frank M Sacks Journal: J Clin Endocrinol Metab Date: 2021-07-13 Impact factor: 5.958
Authors: Stefan J Schunk; Juliane Hermann; Tamim Sarakpi; Sarah Triem; Michaela Lellig; Eunsil Hahm; Stephen Zewinger; David Schmit; Ellen Becker; Julia Möllmann; Michael Lehrke; Rafael Kramann; Peter Boor; Peter Lipp; Ulrich Laufs; Winfried März; Jochen Reiser; Joachim Jankowski; Danilo Fliser; Thimoteus Speer; Vera Jankowski Journal: J Am Soc Nephrol Date: 2021-09-29 Impact factor: 10.121
Authors: Alexander V Sorokin; Sotirios K Karathanasis; Zhi-Hong Yang; Lita Freeman; Kazuhiko Kotani; Alan T Remaley Journal: FASEB J Date: 2020-06-26 Impact factor: 5.191
Authors: Manja Koch; Steven T DeKosky; Matthew Goodman; Jiehuan Sun; Jeremy D Furtado; Annette L Fitzpatrick; Rachel H Mackey; Tianxi Cai; Oscar L Lopez; Lewis H Kuller; Kenneth J Mukamal; Majken K Jensen Journal: JAMA Netw Open Date: 2020-07-01